Ataluren: Time for a 'no-nonsense' approach to heart diseases

Cardiovascular Drugs and Therapy

Volumn 27, Issue 2, 2013, Pages 181-182

  Loudon, John A ^a  

^a Wetherill Park Medical Centre   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ATALUREN; DESMOPLAKIN; RAS PROTEIN;

CARDIOMYOPATHY; CLINICAL EFFECTIVENESS; DRUG EFFICACY; GENETIC SCREENING; GENOME ANALYSIS; HEART ARRHYTHMIA; HEART DISEASE; HEART PROTECTION; HUMAN; LETTER; MAROTEAUX LAMY SYNDROME; NONSENSE MUTATION; ONCOGENE RAS; PERSONALIZED MEDICINE; PRIORITY JOURNAL; TRANSLATIONAL RESEARCH; TREATMENT PLANNING;

CODON, NONSENSE; HEART DISEASES; HUMANS; OXADIAZOLES;

EID: 84878284383     PISSN: 09203206     EISSN: 15737241     Source Type: Journal    
DOI: 10.1007/s10557-012-6435-8     Document Type: Letter

References (5)

1. Loudon JA. Cancer: A novel "no-nonsense" approach to treatment. Oncol Res. 2010;19:55-66.
2. Koopmann TT, Verkerk AO, Bezzina CR, de Bakker JM, Wilde AA. The chemical compound PTC124 does not affect cellular electrophysiology of cardiac ventricular myocytes. Cardiovasc Drugs Ther. 2012;26:41-5.
3. Bartolomeo R, Polishchuk EV, Volpi N, Polishchuk RS, Auricchio A. Pharmacological read-Through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis. 2012.
4. Loudon JA. A novel prosurvival model for cancer under environmental challenge: the 'heart-felt' message for therapeutic intervention. Oncol Res. 2011;19:407-43.
5. NormanM, SimpsonM,Mogensen J, et al. Novel mutation in desmoplakin causes arrhythmogenic left ventricular cardiomyopathy. Circulation. 2005;112:636-42.